Eiman Jahangir, MD (Cardiovascular Medicine) will be one of a six-person crew on the launch on the 11-minute suborbital space flight. He will experience weightlessness for several minutes and get views of planet Earth that little more than 700 people have witnessed.
Vanderbilt University Medical Center is one of roughly 60 study sites worldwide participating in RESPONDER-HF, a randomized clinical trial of an atrial shunt to treat heart failure patients.
Patients with a form of heart failure called HFpEF may breathe normally at rest but quickly become breathless with physical activity. The study will test an atrial shunt to relieve high pressure in the heart.
The testing is for younger patients who may be at risk for inherited cardiomyopathy or arrhythmia syndromes. Without treatment, younger patients may develop other serious cardiac disorders such as heart failure or life-threatening ventricular arrhythmias.
The research shows that by getting enough sleep and reducing variability around sleep onset and wake times, patients can reduce the incidence of chronic disease. Insufficient, irregular and poor-quality sleep is associated with many chronic conditions, including obesity, atrial fibrillation, hypertension, major depressive disorder and generalized anxiety disorder. Those were the main conclusions of a study recently published in the journal Nature Medicine from corresponding author Evan Brittain, MD, MSCI, professor of Medicine.
The researchers tested the feasibility of using a simple set of proteins from blood to capture a molecular fingerprint of cardiorespiratory fitness.
Researchers at Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System have demonstrated in a small clinical study that “turning up the heat” on fat may help people lose weight and reduce their risk of obesity-related cardiovascular and metabolic disease.
Associate professor of Medicine and Radiology and director of Cardio-Oncology Eiman Jahangir, MD, MPH, has been selected by the organization MoonDAO to go into space aboard the Blue Origin rocket, New Shepard, after being chosen in a worldwide contest.
An anticancer drug blunted atherosclerosis progression — and even made plaques shrink — in a mouse model of the disease, opening new opportunities for preventing and treating this leading cause of death.
A multicenter study led by Vanderbilt University Medical Center and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure, a leading cause of hospitalization and death.
Vanderbilt’s Kathryn Lindley, MD, has worked with the American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention to develop a national toolkit for non-obstetricians to better identify and treat pregnant and postpartum patients with cardiovascular emergencies.
